​

Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SRPT Stock Forecast

Sarepta Therapeutics (SRPT) stock forecast, based on 51 Wall Street analysts, predicts a 12-month average price target of $181.80, with a high of $202.00 and a low of $165.00. This represents a 237.04% increase from the last price of $53.94.

$50 $90 $130 $170 $210 $250 High: $202 Avg: $181.8 Low: $165 Last Closed Price: $53.94

SRPT Stock Rating

Sarepta Therapeutics stock's rating consensus is Buy, based on 51 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 39 Buy (76.47%), 12 Hold (23.53%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 51 0 12 39 Strong Sell Sell Hold Buy Strong Buy

SRPT Price Target Upside V Benchmarks

TypeNameUpside
StockSarepta Therapeutics237.04%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--25
Avg Price Target--$179.60
Last Closing Price$53.94$53.94$53.94
Upside/Downside--232.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2581231-24
Mar, 2591211-23
Feb, 25911-1-21
Jan, 25912-1-22
Dec, 241012-1-23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 27, 2024Biren AminPiper Sandler$182.00$136.8732.97%237.41%
Nov 27, 2024Gil BlumNeedham$202.00$136.8747.59%274.49%
Nov 07, 2024Brian SkorneyRobert W. Baird$193.00$124.9554.46%257.80%
Nov 07, 2024Kristen KluskaCantor Fitzgerald$167.00$124.9533.65%209.60%
Oct 21, 2024Andrew TsaiJefferies$165.00$127.0829.84%205.90%
Aug 08, 2024Gavin Clark-GartnerEvercore ISI$179.00$136.4031.23%231.85%
Aug 08, 2024Biren AminPiper Sandler$200.00$140.0642.80%270.78%
Aug 08, 2024Gena WangBarclays$203.00$140.0644.94%276.34%
Aug 08, 2024Brian AbrahamsRBC Capital$181.00$140.0629.23%235.56%
Jul 29, 2024Brian AbrahamsRBC Capital$182.00$147.8823.07%237.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 03, 2025RBC CapitalSector PerformSector Performhold
Apr 02, 2025H.C. WainwrightNeutralupgrade
Mar 18, 2025RBC CapitalOutperformOutperformhold
Mar 07, 2025ScotiabankSector Performinitialise
Dec 02, 2024BMO CapitalOutperformOutperformhold
Nov 27, 2024Piper SandlerOverweightOverweighthold
Nov 27, 2024NeedhamBuyBuyhold
Nov 07, 2024Cantor FitzgeraldNeutralOverweightupgrade
Oct 21, 2024Raymond JamesUnderperformUnderperformhold
Oct 21, 2024RBC CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-3 $4 $11 $18 $25 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.11$-5.15$-8.03$-5.80$2.47----
Avg Forecast$-6.55$-5.11$-8.06$-6.57$2.41$11.64$15.52$14.87$15.91
High Forecast$-6.11$-4.77$-6.17$-6.18$2.94$16.50$21.20$18.54$17.88
Low Forecast$-7.25$-5.66$-8.95$-7.57$1.72$3.67$10.82$10.96$12.75
Surprise %8.55%0.78%-0.37%-11.72%2.49%----

Revenue Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$540.10M$701.89M$933.01M$1.24B$1.90B----
Avg Forecast$540.17M$695.42M$924.70M$1.23B$1.83B$3.12B$3.94B$4.20B$4.43B
High Forecast$584.61M$752.63M$1.00B$1.24B$1.86B$3.42B$3.95B$4.22B$4.85B
Low Forecast$512.45M$659.73M$758.15M$1.21B$1.77B$2.39B$3.93B$4.19B$3.75B
Surprise %-0.01%0.93%0.90%0.86%4.10%----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-554.13M$-418.78M$-703.49M$-535.98M$235.24M----
Avg Forecast$-604.74M$-435.96M$-421.18M$-535.98M$215.18M$1.10B$1.54B$1.66B$1.47B
High Forecast$-564.40M$-348.77M$-336.95M$-428.78M$271.43M$1.52B$1.96B$1.71B$1.65B
Low Forecast$-669.42M$-523.15M$-505.42M$-643.17M$158.93M$338.71M$999.68M$1.01B$1.18B
Surprise %-8.37%-3.94%67.03%-9.32%----

SRPT Forecast FAQ

Is Sarepta Therapeutics stock a buy?

Sarepta Therapeutics stock has a consensus rating of Buy, based on 51 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 39 Buy, 12 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sarepta Therapeutics is a favorable investment for most analysts.

What is Sarepta Therapeutics's price target?

Sarepta Therapeutics's price target, set by 51 Wall Street analysts, averages $181.8 over the next 12 months. The price target range spans from $165 at the low end to $202 at the high end, suggesting a potential 237.04% change from the previous closing price of $53.94.

How does Sarepta Therapeutics stock forecast compare to its benchmarks?

Sarepta Therapeutics's stock forecast shows a 237.04% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Sarepta Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 50.00% Buy, 12.50% Hold, 4.17% Sell, 0% Strong Sell.
  • March 2025: 39.13% Strong Buy, 52.17% Buy, 4.35% Hold, 4.35% Sell, 0% Strong Sell.
  • February 2025: 42.86% Strong Buy, 52.38% Buy, 0% Hold, 4.76% Sell, 0% Strong Sell.

What is Sarepta Therapeutics’s EPS forecast?

Sarepta Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $11.64, marking a 371.26% increase from the reported $2.47 in 2024. Estimates for the following years are $15.52 in 2026, $14.87 in 2027, and $15.91 in 2028.

What is Sarepta Therapeutics’s revenue forecast?

Sarepta Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.12B, reflecting a 64.07% increase from the reported $1.9B in 2024. The forecast for 2026 is $3.94B, followed by $4.2B for 2027, and $4.43B for 2028.

What is Sarepta Therapeutics’s net income forecast?

Sarepta Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $1.1B, representing an 367.14% increase from the reported $235.24M in 2024. Projections indicate $1.54B in 2026, $1.66B in 2027, and $1.47B in 2028.